What Was Recalled and Why
A chemotherapy drug used across a long list of cancers has been recalled in three lots because vials may contain steel particles, and the first thing patients should know is that no one has been reported hurt.
Sunny Pharmtech, based in Taoyuan City, Taiwan, is voluntarily recalling three lots of Cyclophosphamide for Injection, USP, in 1 gram and 2 gram single-dose vials, marketed under the Long Grove Pharmaceuticals brand name. The recall was announced on July 24 and posted by the FDA the same day. The company states that no adverse events or injuries associated with the particulate issue have been reported.
The recall is to the user level, meaning it reaches hospitals, pharmacies and infusion centers rather than stopping at a warehouse. Providers are instructed to stop using and dispensing the product immediately, quarantine affected inventory, and arrange return through Cardinal Health, the distributor.
The three recalled lots are C23019V1 and C24015V1, both 1 gram vials under NDC 81298-8112-1, and V24010V1, a 2 gram vial under NDC 81298-8114-1.
The company's risk statement is direct about why particulate matter in an intravenous drug is serious: "There is a reasonable probability for serious adverse events, including death" if a patient receives an infusion containing it. The complications it names are phlebitis, granuloma, and vessel occlusion or life-threatening blood clots.
Why the Recall Reaches Patients Now
The timing detail in this recall is the one most coverage skips, and it explains why a two-year-old shipment matters this week.
The affected lots were distributed to wholesalers, distributors, hospitals and pharmacies between May and October of 2024. But they do not expire for some time. The C23019V1 lot remains within expiry until October 2026, V24010V1 until March 2027, and C24015V1 until April 2027.
That means these vials could plausibly still be sitting on a shelf in an active inventory. A recall of expired product would be housekeeping. A recall of unexpired product in a drug given by infusion is a live inventory problem, which is why the notice went to the user level.
The population the company identifies as most at risk is the one receiving the drug: cancer patients who often have other medical conditions and may be immunosuppressed from current or prior treatment, or nutritionally depleted by their disease. In that group, a complication that a healthy person might tolerate can escalate.
The One Question Worth Asking
For a patient scheduled for an infusion, there is a single useful question, and it is narrow enough to ask without derailing an appointment.
Ask whether the pharmacy or infusion center has checked its cyclophosphamide inventory against the three recalled lot numbers: C23019V1, C24015V1 and V24010V1.
Hospital pharmacies handle recalls as routine operational work, and most will have already done this within days of the notice. The question is not an accusation, and the likely answer is yes. Asking it costs nothing and gives a patient something concrete to do with the anxiety a chemotherapy recall creates.
Two supporting details make the question easier to ask. The drug is manufactured by Sunny Pharmtech and sold under the Long Grove Pharmaceuticals label, so a center using a different manufacturer's cyclophosphamide is not affected. And the recall covers three specific lots, not the drug generally, so a center can hold the same product from unaffected lots and continue treating normally.
Patients who want to raise it in writing can ask through a patient portal message rather than waiting for the next visit.
Who Takes This Drug
Cyclophosphamide has an unusually wide range of uses, and the recall consequently touches more patients than a narrowly indicated drug would.
According to the labeling described in the recall notice, it is indicated for malignant lymphomas including Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma and Burkitt's lymphoma. It is also indicated for multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of the ovary, retinoblastoma and breast carcinoma.
One indication outside oncology deserves flagging because it involves children. The drug is also indicated for minimal change nephrotic syndrome in pediatric patients with biopsy-proven disease who did not respond adequately to, or could not tolerate, corticosteroid therapy. Families of children receiving cyclophosphamide for a kidney condition rather than cancer are equally covered by this recall and equally entitled to ask the lot question.
Neuroblastoma and retinoblastoma are also predominantly pediatric cancers, so a meaningful share of the affected population is children.
What Not to Do
The most likely harm from this recall is not the particulate. It is a patient deciding independently to skip or delay treatment.
The company's own notice tells patients not to stop or change prescribed treatment without consulting a healthcare professional. That is the operative instruction. Interrupting a chemotherapy cycle has real consequences for how well treatment works, and those consequences are far more predictable than the risk from a recall that has produced no reported injuries.
Nobody should cancel an infusion appointment, delay a scheduled cycle, or ask to switch drugs because of this notice. Any change to a cancer treatment plan belongs to the treating oncologist.
Anyone who has already received cyclophosphamide and feels unwell should contact their care team and describe the symptoms, as they would with any treatment side effect. Signs worth reporting promptly include new pain, redness or swelling along the vein used for infusion, shortness of breath, chest pain, or swelling in an arm or leg, since those could indicate the vascular complications the company named. This is guidance to seek advice, not a basis for self-diagnosis.
Patients or providers can report problems to the FDA's MedWatch program online or by calling 1-800-332-1088. Questions about the recall itself go to Sunny Pharmtech at its listed contact.
The confirmed facts are a voluntary nationwide recall of three unexpired lots for steel particulate, with no reported injuries. Those most affected are patients receiving cyclophosphamide by infusion, including children treated for neuroblastoma, retinoblastoma, or nephrotic syndrome. A reasonable action is to ask whether the infusion center checked the three lot numbers. The central uncertainty is how much affected product remains in inventory. The next expected development is the FDA's classification of the recall in a forthcoming enforcement report.
Related MedicalDaily.com Coverage
Frequently Asked Questions
Which lots were recalled? C23019V1 and C24015V1 in 1-gram vials, and V24010V1 in 2-gram vials, all Cyclophosphamide for Injection, USP from Sunny Pharmtech.
Has anyone been harmed? No adverse events or injuries related to the particulate have been reported, according to the company announcement.
Should I stop my chemotherapy? No. The notice tells patients not to stop or change prescribed treatment without consulting a healthcare professional. Interrupting a cycle carries its own risk.
What should I ask my infusion center? Whether they have checked their cyclophosphamide inventory against lots C23019V1, C24015V1 and V24010V1.
Why does a 2024 shipment matter now? The lots do not expire until October 2026, March 2027 and April 2027, so they could still be in active inventory.
Does this affect children? Yes. The drug treats neuroblastoma, retinoblastoma, and, outside cancer, minimal change nephrotic syndrome in some pediatric patients.
What symptoms should I report? New pain, redness or swelling at the infusion site, shortness of breath, chest pain, or limb swelling. Contact your care team rather than waiting.
